Program Description
Pulmonary Arterial Hypertension (PAH) is a rare and progressive disease that affects the small pulmonary arterioles. It is challenging to diagnose and complex to manage. This accredited CE activity will review the pathophysiology and classifications of PAH, along with current therapies and the management of common side effects. Disparities in care will also be addressed, as well as how risk assessment is calculated and used to help achieve and maintain a low-risk status—an essential treatment goal for patients with PAH.

Intended Audience
The intended audience includes nurse practitioners, nurses, physician assistants and other providers involved in the management of patients with pulmonary arterial hypertension (PAH).

Educational Objectives
After completing of the educational activity, participants should be able to:

  • Identify the newest diagnostic criteria and classification of PAH.
  • Plan effective care for patients with PAH that considers the side effect profile, method of dosing and administration, adverse events, and disparities.
  • Summarize updated treatment pathways and therapeutic targets in the management of PAH.

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
ANCC contact hours.

Physician Associate
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1.0 contact hour(s) (which includes .5 hour(s) of pharmacology)

Commercial Supporter
This activity is supported by an educational grant from Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., and Johnson & Johnson.

Faculty

image Martha Kingman, FNP-C, DNP
Family Nurse Practitioner
Retired after 24 years from University of Texas Southwestern Medical Center
Dallas, TX, Pulmonary Hypertension Clinic

Ms. Kingman has disclosed the following relevant financial relationships:
Consultant: Gossamer Bio, Merck Pharmaceuticals
Speaker: Merck Pharmaceuticals

image Sandra Lombardi, RN
Clinical Care Coordinator
Pulmonary Vascular Program
University of California, San Diego
San Diego, CA

Ms. Lombardi has nothing to disclose.

Conflict of Interest Disclosure Policy
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Accredited Provider, Planners’ and Managers’ Disclosures
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has nothing to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has nothing to disclose.
Laurel Ritley, AKH Project Manager/Reviewer: has nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.